Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- NA
Clinical Trials Related to Metastatic Colorectal Cancer
Related studies linked through entity extraction aliases.
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Intermittent Versus Continuous Tarceva Study
- Status
- COMPLETED
- Phase
- PHASE2
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
- Status
- COMPLETED
- Phase
- PHASE3
Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy
- Status
- COMPLETED
- Phase
- PHASE2
RSHF in Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- NA
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
- Status
- COMPLETED
- Phase
- PHASE2
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2
Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- NA
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
- Status
- COMPLETED
- Phase
- N/A
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
- Status
- COMPLETED
- Phase
- PHASE1